research project

CANDY, a Horizon 2020 project

Many developmental brain diseases co-occur, meaning that if a person has one of those diseases they are quite likely to also have another one. For instance, in autism spectrum disease, the combination of intellectual disability and epilepsy is associated with a reduction in lifespan of about 20 years; and an economic cost that is greater than cancer, stroke, or dementia. Yet, the research spend on neurodevelopmental diseases is less than 1% of the spending on cancer, stroke and dementia.

CANDY’s (Comorbid Analysis of Neurodevelopmental Disorders and Epilepsy) innovation is to test, for the first time, if those diseases and their common mental and bodily co-symptoms, are caused by combinations of common and rare genetic variants and immune activation acting at different ‘sensitive periods’. 

logo candy project

The role of Noldus

Noldus will further develop its innovative tools for neuroscience research using animal models to support the research in this project. Specifically it will improve the integration of physiology and behavioral measurements in its EthoVision XT software as well as developing better tracking in EthoVision.

More information

To find out more, you can contact us directly or visit the project website. If you think Noldus might be a good partner for your consortium, please see here.


  • Radboud University Medical Centre, Nijmegen (Project Leader)
  • King's College London
  • Pasteur Institute
  • University of Basel
  • University of Groningen
  • University of Gent
  • Karolinska Institute
  • Assistance Publique des Hôpitaux de Paris
  • University of Ulm
  • CEA
  • Autism Europe
  • Noldus Information Technology
  • Birkbeck College, London


This project is funded by the Horizon 2020 research program of the European Union under grant number 847818.

Horizon 2020

logo candy project